The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer
Paclitaxel-cisplatin-bevacizumab is effective and tolerable as a first-line treatment for platinum-naïve primary stage IVB cervical cancer. Cervical mass size reduction rate ≥40 % during paclitaxel-cisplatin-bevacizumab treatment might be a potential prognostic factor for PFS in patients with platinum-naïve primary stage IVB cervical cancer.
Authors
- Shin‐Wha Lee (ORCID: https://orcid.org/0000-0002-5088-1905)
- Jeong‐Yeol Park (ORCID: https://orcid.org/0000-0003-2475-7123)
- Jun Hwan Kim (ORCID: https://orcid.org/0000-0002-1162-8616)
- E. Park
- Yong‐Man Kim
- Jong-Hyeok Kim (ORCID: https://orcid.org/0000-0001-5179-0848)
- Dae‐Yeon Kim (ORCID: https://orcid.org/0000-0002-8068-3475)
- Dae‐Shik Suh (ORCID: https://orcid.org/0000-0003-1861-3203)
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- National Cancer Center (KR)
Publication Details
- Journal
- Taiwanese Journal of Obstetrics and Gynecology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.tjog.2020.07.035
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17